Regeneron Pharmaceuticals | REGN

Stock Price
654.07
Daily Change
29.35 4.70%
Monthly
5.67%
Yearly
19.50%
Q3 Forecast
619.74

EPS Reference Time Actual Consensus Previous
2026-04-29 FY2026Q1 AM 9.47 9.13 8.22
2026-01-30 FY2025Q4 AM 11.44 10.61 12.07
2025-10-28 FY2025Q3 AM 11.83 9.67 12.46
2025-08-01 FY2025Q2 AM 12.89 8.60 11.56
2025-04-29 FY2025Q1 AM 8.22 9.55 9.55



Peers Price Chg Day Year Date
Kyowa Hakko Kirin 2,631.00 66.50 2.59% 5.54% Jul/02
Astellas Pharma 2,139.50 20.00 0.94% 53.75% Jul/02
AbbVie 261.07 10.01 3.99% 37.93% Jul/02
Agenus 3.49 0.08 2.35% -42.50% Jul/02
Agios Pharmaceuticals 37.58 0.50 1.35% 4.19% Jul/02
Alnylam Pharmaceuticals 312.78 11.11 3.68% -5.76% Jul/02
Amgen 374.15 12.82 3.55% 25.45% Jul/02
AstraZeneca 14,538.00 684.00 4.94% 42.47% Jul/02
Biogen 216.12 6.38 3.04% 62.66% Jul/02
BioMarin Pharmaceutical 59.00 1.18 2.04% 2.61% Jul/02

Indexes Price Day Year Date
US500 7483 0.01 0.0001% 19.17% Jul/02
USND 25833 -207.36 -0.80% 25.39% Jul/02
US100 29280 -479.92 -1.61% 28.05% Jul/02

Regeneron Pharmaceuticals traded at $654.07 this Thursday July 2nd, increasing $29.35 or 4.70 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals gained 5.67 percent. Over the last 12 months, its price rose by 19.50 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 619.74 by the end of this quarter and at 581.86 in one year, according to Trading Economics global macro models projections and analysts expectations.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.